🔎 Trials Near Me

Domov › Rak jajčnikov › Rhode Island

Klinične študije za Rak jajčnikov v Rhode Island

16 študij za Rak jajčnikov išče udeležence na lokacijah v Rhode Island.

Mesta v Rhode Island

Uradno besedilo študije (angleško)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Women and Infants Hospital, Providence
  • Roger Williams Medical Center, Providence
Vključevanje udeležencevFaza 2
Vse starosti · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05564377

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

  • Women & Infants Hospital /ID# 277930, Providence
Vključevanje udeležencevFaza 2
Starost 18 in več · Ženske · Posodobljeno 1. okt. 2026 · NCT07024784

TLR9 Immunotherapy for Peritoneal Carcinomatosis

  • Rhode Island and the Miriam Hospitals (Brown University Health), Providence
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07658196

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Women & Infants Hospital, Providence
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07213804

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  • Women & Infants Hospital ( Site 0001), Providence
Vključevanje udeležencevFaza 3
Starost 18 in več · Ženske · Posodobljeno 17. sep. 2026 · NCT07318558

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  • Research Site, Providence
Vključevanje udeležencevFaza 1/2
Starost 18–130 · Vsi spoli · Posodobljeno 21. avg. 2026 · NCT05797168

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • Smilow Cancer Hospital Care Center - Westerly, Westerly
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT07001748

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Women and Infants Hospital, Providence
Vključevanje udeležencev
Starost 35–50 · Ženske · Posodobljeno 7. avg. 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Women and Infants Hospital, Providence
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 7. avg. 2026 · NCT06580314

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Women and Infants Hospital of Rhode Island, Providence
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 4. avg. 2026 · NCT05579366

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • Lifespan Cancer Institute - Rhode Island Hospital, Providence
Vključevanje udeležencevFaza 2
Starost 8 in več · Vsi spoli · Posodobljeno 27. jul. 2026 · NCT05503797

Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

  • Women's and Infant's Hospital, Providence
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 50–74 · Ženske · Posodobljeno 6. maj 2026 · NCT00539162

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

  • Site 0191, Providence
Vključevanje udeležencevFaza 1
Starost 18 in več · Ženske · Posodobljeno 7. apr. 2026 · NCT04516447

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Providence
Vključevanje udeležencevOpazovalna študija
Vse starosti · Vsi spoli · Posodobljeno 28. okt. 2025 · NCT03452774

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.